Office of the Director; Notice of Charter Renewal, 17269 [2017-07054]
Download as PDF
<![CDATA[
Federal Register / Vol. 82, No. 67 / Monday, April 10, 2017 / Notices
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Infectious Diseases, 5601 Fishers Lane,
Rockville, MD 20852; tel. 301–496–
2644. A signed Confidential Disclosure
Agreement will be required to receive
copies of unpublished patent
applications.
SUPPLEMENTARY INFORMATION:
Technology descriptions follows.
Compositions and Methods for
Detecting Loa Loa
Description of Technology: Loa loa is
a filarial nematode estimated to infect
3–13 million people in Central and
Western Africa. In parts of Africa, mass
administration of ivermectin is common
for onchocerciasis and lymphatic
filariasis control. However, some
individuals infected with Loa loa
microfilariae in high densities are
known to experience post-ivermectin
severe adverse events, such as
encephalopathy, coma, or even death.
Therefore, diagnostic tools that can
accurately identify and differentiate Loa
loa microfilariae from other filarial
infections are needed. Microscopic
evaluation of blood samples is the only
current diagnostic method used to
detect Loa loa microfilaremia in
endemic areas, and is impractical for
widespread screening. Molecular based
assays are useful and are quantitative,
but require the use of sophisticated
instrumentation.
The inventors analyzed samples from
Loa loa infected patients and uninfected
controls, and have identified Loa loa
microfilaria-specific antigens. The
pending application claims a variety of
means of detecting these antigens.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Diagnostics
Competitive Advantages:
• Highly specific to Loa loa
microfilariae
• Highly sensitive
• Both diagnostic and quantitative
• Works with blood, urine, or saliva
sample
Development Stage:
• Pre-Clinical
Inventors: Thomas B. Nutman, NIAID,
NIH; Sasisekhar Bennuru, NIAID, NIH;
and Papa Makhtar Drame, NIAID, NIH.
Publications: Drame, Papa, et al. 2016.
Identification and Validation of Loa loa
Microfilaria-Specific Biomarkers: A
Rational Design Approach Using
Proteomics and Novel Immunoassays.
mBio, vol. 7 no. 1 e02132–15.
Intellectual Property: HHS Reference
No. E–140–2015/0—US Provisional
VerDate Sep<11>2014
20:02 Apr 07, 2017
Jkt 241001
Patent Application No. 62/153,654 filed
April 28, 2015; PCT Patent Application
No. PCT/US2016/029673 filed April 28,
2016.
Licensing Contact: James M.
Robinson, 301–761–7542;
James.Robinson4@nih.gov.
Collaborative Research Opportunity:
The Technology Transfer and
Intellectual Property Office (TTIPO) is
seeking parties interested in
collaborative research to further
develop, evaluate or commercialize a
diagnostic means for detecting Loa loa
microfilaria-specific antigens. For
collaboration opportunities, please
contact James M. Robinson, 301–761–
7542; James.Robinson4@nih.gov.
Dated: March 28, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and
Intellectual Property Office, National Institute
of Allergy and Infectious Diseases.
[FR Doc. 2017–07058 Filed 4–7–17; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter
Renewal
In accordance with Title 41 of the
U.S. Code of Federal Regulations,
Section 102–3.65(a), notice is hereby
given that the Charter for the Center for
Scientific Review Advisory Council
(CSRAC) was renewed for an additional
two-year period on March 31, 2017.
It is determined that the CSRAC is in
the public interest in connection with
the performance of duties imposed on
the National Institutes of Health by law,
and that these duties can best be
performed through the advice and
counsel of this group.
Inquiries may be directed to Jennifer
Spaeth, Director, Office of Federal
Advisory Committee Policy, Office of
the Director, National Institutes of
Health, 6701 Democracy Boulevard,
Suite 1000, Bethesda, Maryland 20892
(Mail Code 4875), Telephone (301) 496–
2123, or spaethj@od.nih.gov.
Dated: April 4, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
17269
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Heart, Lung, and Blood
Institute; Notice of Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the Sleep
Disorders Research Advisory Board.
The meeting will be open to the
public, with attendance limited to space
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting.
Name of Committee: Sleep Disorders
Research Advisory Board.
Date: June 22–23, 2017.
Time: June 22, 2017, 1:00 p.m. to 5:00 p.m.
Agenda: Update on NIH sleep disorders
research programs and initiatives, updates on
sleep related activities from selected Federal
Agency partners, and discussion of the NIH
Sleep Disorders Research Plan.
Place: National Institutes of Health, Two
Rockledge Center, Conference Room 9100/
9104, 6701 Rockledge Drive, Bethesda, MD
20892.
Time: June 23, 2017, 8:00 a.m. to 3:00 p.m.
Agenda: Discussion and updates on the
NIH Sleep Disorders Research Plan, and
potential directions for inter-agency
coordination activities.
Place: National Institutes of Health, Two
Rockledge Center, Conference Room 9100/
9104, 6701 Rockledge Drive, Bethesda, MD
20892.
Contact Person: Michael J. Twery, Ph.D.,
Director, National Center on Sleep Disorders
Research, Division of Lung Diseases, National
Heart, Lung, and Blood Institute, National
Institutes of Health, 6701 Rockledge Drive,
Suite 10170, Bethesda, MD 20892–7952, 301–
435–0199, twerym@nhlbi.nih.gov.
Information is also available on the
Institute’s/Center’s home page: https://
www.nhlbi.nih.gov/about/committees/sdrab/,
where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.233, National Center for
Sleep Disorders Research; 93.837, Heart and
Vascular Diseases Research; 93.838, Lung
Diseases Research; 93.839, Blood Diseases
and Resources Research, National Institutes
of Health, HHS)
[FR Doc. 2017–07054 Filed 4–7–17; 8:45 am]
Dated: April 4, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory
Committee Policy.
BILLING CODE 4140–01–P
[FR Doc. 2017–07056 Filed 4–7–17; 8:45 am]
PO 00000
BILLING CODE 4140–01–P
Frm 00092
Fmt 4703
Sfmt 9990
E:\FR\FM\10APN1.SGM
10APN1
]]>Agencies
[Federal Register Volume 82, Number 67 (Monday, April 10, 2017)]
[Notices]
[Page 17269]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-07054]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Charter Renewal
In accordance with Title 41 of the U.S. Code of Federal
Regulations, Section 102-3.65(a), notice is hereby given that the
Charter for the Center for Scientific Review Advisory Council (CSRAC)
was renewed for an additional two-year period on March 31, 2017.
It is determined that the CSRAC is in the public interest in
connection with the performance of duties imposed on the National
Institutes of Health by law, and that these duties can best be
performed through the advice and counsel of this group.
Inquiries may be directed to Jennifer Spaeth, Director, Office of
Federal Advisory Committee Policy, Office of the Director, National
Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda,
Maryland 20892 (Mail Code 4875), Telephone (301) 496-2123, or
spaethj@od.nih.gov.
Dated: April 4, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-07054 Filed 4-7-17; 8:45 am]
BILLING CODE 4140-01-P
